Subscribe To

Price Alert Latest News Economic Calendar News

NEXI / NexImmune to Present at the Barclays 2022 Global Healthcare Conference

GAITHERSBURG, Md., March 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the Barclays 2022 Global Healthcare Conference on Thursday, March 17, 2022 at 8:30 a.m. Eastern Time. Read More

Demo Live Account See Partner Details

Content Topics

Neximmune

Present

Barclays

2022

Global

Healthcare

Conference

Stock

NEXI

Posted: Mar 10 2022, 16:26

Author Name: GlobeNewsWire

NEXI News

By InvestorPlace
February 16, 2023

Why Is NexImmune (NEXI) Stock Up 65% Today?

NexImmune (NASDAQ: NEXI ) stock is rocketing higher on Thursday following the release of positive preclinical trial data. According to a press release

By InvestorPlace
January 20, 2023

Why Is NexImmune (NEXI) Stock Down 4% Today?

NexImmune (NASDAQ: NEXI ) stock is falling on Friday as the immunotherapies company's shares come off of a recent high earlier this week. The NEXI sto

By InvestorPlace
July 15, 2022

Why Is NexImmune (NEXI) Stock Up 30% Today?

NexImmune appears to be making headway in the company's ongoing battle against HPV-related cancers -- and NEXI stock is heading higher today. The post

By Benzinga
March 17, 2022

NexImmune, Zephyr Join Forces For Oncology Target Discovery, Validation

NexImmune Inc (NASDAQ: NEXI) and Zephyr AI have announced a strategic partnership focusing on discovering and validating novel targets for new T-c

By GlobeNewsWire
March 10, 2022

NexImmune to Present at the Barclays 2022 Global Healthcare Conference

GAITHERSBURG, Md., March 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel appro

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.